The Fat-Burning Peptide No One’s Talking About – AOD-9604 for Targeted Fat Loss
A short solo talk in which Chancellor Harn describes AOD-9604, a growth hormone fragment, and how he says it may fit alongside GLP-1 drugs or help with weight loss plateaus.
With Chancellor Harn (ND, MS)
Key moments
Tap a moment to play the video from there.
- 0:00Introduction and scope of the talkHarn introduces AOD-9604 as a weight loss peptide that he says does not suppress appetite or stimulate the central nervous system. He lists mechanism, use, side effects and suitable patients as topics.
- 0:28A fragment of growth hormoneHe says AOD-9604 is the part of human growth hormone responsible for fat loss, located at roughly amino acids 176 or 177 to 191. He links falling growth hormone with harder fat loss in older people.
- 1:34How it triggers fat breakdownHarn describes a pathway through cyclic AMP, protein kinase A and hormone-sensitive lipase inside fat cells. He says it reaches the same pathway adrenaline does, without stimulants.
- 2:34Blocking new fat storageHe says AOD-9604 can block enzymes including free fatty acid synthase and acetyl-CoA carboxylase. According to him, this limits the storage of consumed carbohydrates as fat.
- 3:14Pairing with GLP-1 drugsHarn says GLP-1 drugs hit dose and side effect limits, and that AOD-9604 acts on a different mechanism. He argues it could complement them by releasing and burning stored fat.
- 4:17Weight loss plateausHe says he finds the peptide helpful for people who plateau, including those not on a GLP-1 drug. He ties plateaus to the body resisting rapid weight loss.
- 4:55What it does not doHarn contrasts AOD-9604 with growth hormone and secretagogue peptides, which he says can add muscle, affect blood glucose and cause water retention. He says AOD-9604 avoids these effects.
- 6:08Conclusion and clinical thoughtsHe sums it up as a precision peptide for fat loss that does not affect appetite, blood sugar or calorie intake. He suggests it for people on GLP-1 drugs, on hormone replacement therapy, or on nothing else.
What the video says
Chancellor Harn, a naturopathic doctor, presents AOD-9604 as a peptide made for weight loss. He describes it as a fragment of human growth hormone, covering the amino acid stretch from about position 176 or 177 to 191, which he says researchers isolated because that portion drives fat breakdown. He says it does not suppress appetite or stimulate the central nervous system.
Harn then explains the mechanism as he understands it. According to him, AOD-9604 acts inside fat cells to raise cyclic AMP, which signals protein kinase A and then hormone-sensitive lipase, the final step that releases stored fatty acids into the blood. He says this is the same pathway normally triggered through adrenaline receptors, but reached without stimulants such as caffeine, ephedrine, amphetamines or phentermine. He also says the peptide blocks enzymes needed to store carbohydrates and other dietary calories as fat, so it could limit new fat gain as well as promote fat release.
The middle of the talk covers who he thinks might use it. Harn says GLP-1 drugs such as semaglutide, tirzepatide and retatrutide can only be dosed so high before side effects like severe appetite suppression and stomach upset become hard to tolerate. In his view, AOD-9604 works by a different mechanism and could be added to them. He also says he finds it useful for people who are not on a GLP-1 drug but have hit a weight loss plateau.
He closes by contrasting it with growth hormone and growth hormone secreting peptides such as tesamorelin, sermorelin, CJC-1295 and ipamorelin. Harn says those can add muscle, affect blood glucose and cause water retention, while AOD-9604 does not. The talk is a clinician's overview with no data, doses or study results presented, and the video ends with a request for comments and subscribers.
On each compound
AOD-96040:28
Harn describes it as a growth hormone fragment that he says triggers fat breakdown in fat cells and may reduce new fat storage, without appetite suppression, stimulant effects or changes in blood sugar.
See how your DNA reads AOD-9604Semaglutide3:14
Harn names it among effective GLP-1 weight loss drugs whose dosing is limited by side effects, and says AOD-9604 could be added because it works differently.
See how your DNA reads SemaglutideTirzepatide3:14
Harn lists it alongside other GLP-1 drugs as effective but limited by tolerability at higher doses, and says AOD-9604 could complement it.
See how your DNA reads TirzepatideRetatrutide3:14
Harn mentions it as the newer version of the GLP-1 class and groups it with those drugs that AOD-9604 could be paired with.
See how your DNA reads RetatrutideTesamorelin5:07
Harn names it among growth hormone secreting peptides that he says can increase muscle mass, affect blood glucose and cause water retention, unlike AOD-9604.
See how your DNA reads TesamorelinSermorelin5:07
Harn lists it with other growth hormone secreting peptides that he says come with effects AOD-9604 does not have.
See how your DNA reads SermorelinCJC-12955:07
Harn includes it in a list of growth hormone secreting peptides that he says bring muscle gain, glucose effects and water retention.
See how your DNA reads CJC-1295Ipamorelin5:07
Harn includes it in that same list of growth hormone secreting peptides, contrasted with AOD-9604.
See how your DNA reads IpamorelinWhat this video doesn’t settle
- The talk presents no clinical data, trial results, doses or amounts of weight loss, so the claimed effects rest on Harn's description and clinical impression.
- Harn's statements that AOD-9604 pairs well with GLP-1 drugs and breaks plateaus are his own observations, with no evidence shown for combined use.
- The video promises a discussion of side effects but does not describe any for AOD-9604, so its safety profile is not established here.
Questions this video answers
What is AOD-9604 according to Chancellor Harn?
Harn says it is a fragment of human growth hormone, covering the amino acid chain from about the 176th or 177th to the 191st. He says it was isolated because that portion is responsible for fat breakdown.
How does AOD-9604 work to burn fat?
Harn says it enters fat cells and raises cyclic AMP, which acts through protein kinase A to activate hormone-sensitive lipase. He says this releases stored fatty acids without a stimulant, and that it also blocks enzymes involved in storing new fat.
Can AOD-9604 be combined with GLP-1 drugs like semaglutide?
Harn says he finds it useful alongside GLP-1 agonists because it works through a different mechanism. He says it can add fat release and burning when GLP-1 side effects limit how high the dose can go.
How is AOD-9604 different from growth hormone peptides like ipamorelin or sermorelin?
According to Harn, growth hormone and its secreting peptides can increase muscle mass, affect blood glucose and cause water retention. He says AOD-9604 does not do these things.
Does Harn say AOD-9604 has side effects?
He says at the start that he will cover side effects, but the talk mainly describes what he says it does not cause. He names no side effects of AOD-9604 itself.
Video by Chancellor Harn, ND, MS on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
